What is DARZALEX®?
DARZALEX® is a prescription medicine used to treat multiple myeloma:
- In combination with the medicines lenalidomide and dexamethasone or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma.
- Alone in people who have received at least three prior medicines to treat multiple myeloma, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent.
It is not known if DARZALEX® is safe and effective in children.
Important Safety Information
What should I tell my healthcare provider before taking DARZALEX®?
Before you receive DARZALEX®, tell your healthcare provider about all of your medical conditions, including if you:
- have a history of breathing problems
- have had shingles (herpes zoster)
are pregnant or plan to become pregnant. DARZALEX® may harm your unborn baby.
- Females who are able to become pregnant should use an effective method of birth control during treatment and for at least 3 months after your final dose of DARZALEX®. Talk to your healthcare provider about birth control methods that you can use during this time.
- are breastfeeding or plan to breastfeed. It is not known if DARZALEX® passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive DARZALEX®?
- DARZALEX® may be given alone or together with other medicines used to treat multiple myeloma.
- DARZALEX® will be given to you by intravenous (IV) infusion into your vein.
- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
- Your healthcare provider will give you medicines before each dose of DARZALEX® and on the first day after each dose of DARZALEX® to help reduce the risk of infusion reactions.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment
What are the possible side effects of DARZALEX®?
DARZALEX® may cause serious reactions, including:
Infusion reactions. Infusion reactions are common with DARZALEX® and can be severe. Your healthcare provider may temporarily stop your infusion or completely stop treatment with DARZALEX® if you have infusion reactions. Tell your healthcare provider right away if you get any of the following symptoms:
- shortness of breath or trouble breathing
- dizziness or lightheadedness (hypotension)
- throat tightness
- runny or stuffy nose
- Changes in blood tests. DARZALEX® can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX®. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX®. Tell all of your healthcare providers that you are being treated with DARZALEX® before receiving blood transfusions.
- Decreases in blood cell counts. DARZALEX® can decrease white blood cell counts which help fight infections and blood cells called platelets which help to clot blood. Tell your healthcare provider if you develop fever or have signs of bruising or bleeding.
The most common side effects of DARZALEX® include:
- shortness of breath
- muscle spasms
- back pain
- cold-like symptoms (upper respiratory infection)
- nerve damage causing tingling, numbness or pain
- swollen hands, ankles or feet
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of DARZALEX®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of DARZALEX®
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about DARZALEX® that is written for health professionals.
Please see Important Product Information.